常磐病院 血液内科

論文業績一覧（※2023 年 6 月時点）

1. Mizumaki H, Ishiyama K, Aoki J, Mori J, Mizuno S, Doki N, Fukuda T, Uchida N,Onizuka M, Tanaka M, Katayama Y, Ozawa Y, Ikegame K, Takada S, Kawakita T,Aotsuka N, Atsuta Y, Yanada M. Outcomes after allogeneic hematopoietic stem
cell transplantation in acute myeloid leukemia patients with
der(1;7)(q10;p10). EJHaem. 2022 Nov 6;4(1):251-257. doi: 10.1002/jha2.609.
PMID: 36819182; PMCID: PMC9928652.
2. Mori J, Sawada T, Baba T, Hayakawa A, Kanemoto Y, Nishimura K, Amano R, Siril
YJ, Okada M, Kurokawa T, Kato S. Identification of cell cycle-associated and-unassociated regulators for expression of a hepatocellular carcinoma
oncogene cyclin-dependent kinase inhibitor 3. Biochem Biophys Res Commun.
2022 Oct 15;625:46-52. doi: 10.1016/j.bbrc.2022.07.088. Epub 2022 Jul 31.
PMID: 35944363.
3. Sawada T, Kanemoto Y, Amano R, Hayakawa A, Kurokawa T, Mori J, Kato S.
Antagonistic action of a synthetic androgen ligand mediated by chromatin
remodeling in a human prostate cancer cell line. Biochem Biophys Res Commun.
2022 Jul 5;612:110-118. doi: 10.1016/j.bbrc.2022.04.109. Epub 2022 Apr 26.
PMID: 35523048.
4. Kanemoto Y, Nishimura K, Hayakawa A, Sawada T, Amano R, Mori J, Kurokawa T,
Murakami Y, Kato S. A long non-coding RNA as a direct vitamin D target
transcribed from the antisense strand of the human HSD17B2 locus. Biosci Rep.
2022 May 27;42(5):BSR20220321. doi: 10.1042/BSR20220321. PMID: 35510872;
PMCID: PMC9142830.
5. Hayakawa A, Kurokawa T, Kanemoto Y, Sawada T, Mori J, Kato S. Skeletal andgene-regulatory functions of nuclear sex steroid hormone receptors. J Bone
Miner Metab. 2022 May;40(3):361-374. doi: 10.1007/s00774-021-01306-2. Epub
2022 Jan 25. PMID: 35076781.
6. Osawa S, Mori J. Trial of Intensive Blood-Pressure Control in Older Patientswith Hypertension. N Engl J Med. 2021 Dec 30;385(27):2588-2589. doi:
10.1056/NEJMc2117463. PMID: 34965350.
7. Sawada T, Nishimura K, Mori J, Kanemoto Y, Kouzmenko A, Amano R, Hayakawa A,Tokiwa S, Shimmura H, Kato S. Androgen-dependent and DNA-binding-independentassociation of androgen receptor with chromatic regions coding androgeninduced noncoding RNAs. Biosci Biotechnol Biochem. 2021 Sep 22;85(10):21212130. doi: 10.1093/bbb/zbab135. PMID: 34297060.
8. Nishimura K, Mori J, Sawada T, Nomura S, Kouzmenko A, Yamashita K, KanemotoY, Kurokawa T, Hayakawa A, Tokiwa S, Ochi M, Shimmura H, Kato S. Profiling ofAndrogen-Dependent Enhancer RNAs Expression in Human Prostate Tumors: Searchfor Malignancy Transition Markers. Res Rep Urol. 2021 Sep 14;13:705-713. doi:
10.2147/RRU.S328661. PMID: 34549035; PMCID: PMC8449685.
9. Kidoguchi K, Mori J, Tanimoto T. Idecabtagene Vicleucel in Relapsed Myeloma.
N Engl J Med. 2021 Jun 17;384(24):2356-2357. doi: 10.1056/NEJMc2105069. PMID:34133869.
10. Shibusawa M, Kidoguchi K, Mori J, Tanimoto T. PET-guided omission ofradiotherapy in Hodgkin lymphoma. Lancet Oncol. 2021 May;22(5):e181. doi:10.1016/S1470-2045(21)00146-7. PMID: 33932378.
11. Kanemoto Y, Hayakawa A, Sawada T, Amano R, Kurokawa T, Sawatsubashi S,Fukumoto S, Mori J, Kato S. Transcriptional Regulation of 25-Hydroxyvitamin
D-24-Hydroxylase (CYP24A1) by Calcemic Factors in Keratinocytes. J Nutr Sci
Vitaminol (Tokyo). 2021;67(6):424-428. doi: 10.3177/jnsv.67.424. PMID:34980721.
12. Yamasaki S, Mori J, Kanda J, Imahashi N, Uchida N, Doki N, Tanaka M, Katayama
Y, Eto T, Ozawa Y, Takada S, Onizuka M, Hino M, Kanda Y, Fukuda T, Atsuta Y,Yanada M. Effect of allogeneic HCT from unrelated donors in AML patients withintermediate- or poor-risk cytogenetics: a retrospective study from theJapanese Society for HCT. Ann Hematol. 2020 Dec;99(12):2927-2937. doi:
10.1007/s00277-020-04261-6. Epub 2020 Sep 17. PMID: 32940726.
13. Mori J, Kaji S, Kawai H, Kida S, Tsubokura M, Fukatsu M, Harada K, Noji H,Ikezoe T, Maeda T, Matsuda A. Assessment of dysplasia in bone marrow smear
with convolutional neural network. Sci Rep. 2020 Sep 7;10(1):14734. doi:
10.1038/s41598-020-71752-x. PMID: 32895431; PMCID: PMC7477564.
14. Mori J, Oshima K, Kimura S, Ikezoe T. Treatment of T-Cell Prolymphocytic
Leukemia with Central Nervous System Involvement Using Intrathecal
Alemtuzumab Administration. Case Rep Hematol. 2020 Jul 27;2020:8822172. doi:
10.1155/2020/8822172. PMID: 32802528; PMCID: PMC7403948.

15. Mori J, Oshima K, Tanimoto T, Ishizuka H, Kimura S, Miura M, Takahashi N.
Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid
leukemia and chronic kidney disease. Int J Hematol. 2020 Jul;112(1):115-117.
doi: 10.1007/s12185-020-02846-5. Epub 2020 Mar 9. PMID: 32152879.
16. Mori J, Oshima K, Tanimoto T. Cat Rearing: A Potential Risk of Fulminant
Sepsis Caused by Capnocytophaga canimorsus in a Hemodialysis Patient. Case
Rep Nephrol Dial. 2020 May 13;10(2):51-56. doi: 10.1159/000507425. PMID:32518766; PMCID: PMC7265706.
17. Yanada M, Takami A, Mizuno S, Mori J, Chou T, Usuki K, Uchiyama H, Amano I,Fujii S, Miyamoto T, Saito T, Kamimura T, Ichinohe T, Fukuda T, Okamoto S,Atsuta Y, Yano S. Autologous hematopoietic cell transplantation for acute
myeloid leukemia in adults: 25 years of experience in Japan. Int J Hematol.
2020 Jan;111(1):93-102. doi: 10.1007/s12185-019-02759-y. Epub 2019 Oct 14.
PMID: 31612307.
18. Yamasaki S, Aoki J, Mori J, Mizuno S, Uchida N, Ohashi K, Fukuda T, Ikegame
K, Eto T, Ogawa Y, Tanaka M, Hidaka M, Iwato K, Sawa M, Ichinohe T, Kanda Y,Atsuta Y, Yanada M, Yano S; Adult Acute Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell Transplantation. Better disease control
before allogeneic stem cell transplantation is crucial to improve theoutcomes of transplantation for acute myeloid leukemia patients withextramedullary disease. Bone Marrow Transplant. 2020 Jan;55(1):249-252. doi:
10.1038/s41409-019-0527-z. Epub 2019 Apr 10. PMID: 30971777.
19. Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanomori H, Ozawa Y,Sawa M, Nakamae H, Eto T, Ohta S, Tanaka J, Ichinohe T, Atsuta Y, Takami A.
Role of alternative donor allogeneic hematopoietic stem cell transplantationin patients with intermediate- or poor-risk acute myeloid leukemia in firstcomplete remission. Bone Marrow Transplant. 2019 Dec;54(12):2004-2012. doi:
10.1038/s41409-019-0571-8. Epub 2019 May 31. PMID: 31152148.
20. Yanada M, Mori J, Aoki J, Masuko M, Harada K, Uchida N, Doki N, Fukuda T,Sakura T, Kanamori H, Sawa M, Kondo T, Katayama Y, Kanda J, Ichinohe T,Atsuta Y, Yano S. Allogeneic hematopoietic cell transplantation for patientswith a history of multiple relapses of acute myeloid leukemia. Ann Hematol.
2019 Sep;98(9):2179-2186. doi: 10.1007/s00277-019-03736-5. Epub 2019 Jun 15.
PMID: 31203422.

21. Harada K, Konuma T, Machida S, Mori J, Aoki J, Uchida N, Ohashi K, Fukuda T,Tanaka M, Ikegame K, Ozawa Y, Iwato K, Eto T, Onizuka M, Ichinohe T, Atsuta
Y, Yano S. Risk Stratification and Prognosticators of Acute Myeloid Leukemiawith Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem
Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid
Leukemia Working Group of the Japan Society for Hematopoietic Cell
Transplantation. Biol Blood Marrow Transplant. 2019 Sep;25(9):1730-1743. doi:
10.1016/j.bbmt.2019.04.025. Epub 2019 May 2. PMID: 31054982.
22. Oshima K, Ozaki A, Mori J, Takita M, Tanimoto T. Entrance examination
misogyny in Japanese medical schools. Lancet. 2019 Apr 6;393(10179):1416.
doi: 10.1016/S0140-6736(18)33180-5. Epub 2019 Apr 4. PMID: 30967216.
23. Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y,Ota S, Kanamori H, Mori T, Nakamae H, Eto T, Shiratori S, Maeda T, Iwato K,
Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S. Patients with acute myeloid
leukemia undergoing allogeneic hematopoietic cell transplantation: trends insurvival during the past two decades. Bone Marrow Transplant. 2019Apr;54(4):578-586. doi: 10.1038/s41409-018-0301-7. Epub 2018 Aug 14. PMID:30108330.
24. Sawatsubashi S, Nishimura K, Mori J, Kouzmenko A, Kato S. The Function of theVitamin D Receptor and a Possible Role of Enhancer RNA in Epigenomic
Regulation of Target Genes: Implications for Bone Metabolism. J Bone Metab.
2019 Feb;26(1):3-12. doi: 10.11005/jbm.2019.26.1.3. Epub 2019 Feb 28. PMID:30899718; PMCID: PMC6416145.
25. Kosugi K, Tsuda K, Higuchi A, Mori J, Tanimoto T. Bridge the deep chasm
between patients with cancer and palliative care in Japan. BMJ Support
Palliat Care. 2018 Dec;8(4):494. doi: 10.1136/bmjspcare-2017-001329. Epub2017 Feb 23. PMID: 28232514.
26. Tanimoto T, Mori J, Kurokawa T, Takita M, Oshima K. Predictive geneexpression score for follicular lymphoma. Lancet Oncol. 2018 Jun;19(6):e281.
doi: 10.1016/S1470-2045(18)30324-3. Epub 2018 Jun 1. PMID: 29893256.
27. Okada N, Tanimoto T, Morita T, Higuchi A, Yoshida I, Kosugi K, Maeda Y,Nishikawa Y, Ozaki A, Tsuda K, Mori J, Ohnishi M, Ward LW, Narimatsu H, YujiK, Kami M. A model-based estimation of inter-prefectural migration ofphysicians within Japan and associated factors: A 20-year retrospective

study. Medicine (Baltimore). 2018 Jun;97(22):e10878. doi:
10.1097/MD.0000000000010878. PMID: 29851805; PMCID: PMC6392712.
28. Oshima K, Mori J, Tanimoto T. Letermovir Prophylaxis for Cytomegalovirus. NEngl J Med. 2018 Mar 8;378(10):964. doi: 10.1056/NEJMc1800572. PMID:
29517194.
29. Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, Kurosawa S, Toya T,Kanamori H, Ozawa Y, Ogawa H, Henzan H, Iwato K, Sakura T, Ota S, Fukuda T,Ichinohe T, Atsuta Y, Yano S. Effect of cytogenetic risk status on outcomesfor patients with acute myeloid leukemia undergoing various types ofallogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
Leuk Lymphoma. 2018 Mar;59(3):601-609. doi: 10.1080/10428194.2017.1357173.
Epub 2017 Jul 28. PMID: 28750566.
30. Harada K, Doki N, Aoki J, Mori J, Machida S, Masuko M, Uchida N, Najima Y,Fukuda T, Kanamori H, Ogawa H, Ota S, Ogawa K, Takahashi S, Kasai M, Maeda A,Nagafuji K, Kawakita T, Ichinohe T, Atsuta Y. Outcomes after allogeneic
hematopoietic stem cell transplantation in patients with acute myeloid
leukemia harboring t(7;11)(p15;p15). Haematologica. 2018 Feb;103(2):e69-e72.
doi: 10.3324/haematol.2017.179804. Epub 2017 Nov 16. PMID: 29146707; PMCID:
PMC5792289.
31. Kato S, Nishimura KI, Ochi M, Shimmura H, Mori JI. [Bone and calcium
metabolism associated with malignancy. The function of sex hormone receptors
in sex hormone-dependent cancers.]. Clin Calcium. 2018;28(11):1457-1463.
Japanese. PMID: 30374001.
32. Tanimoto T, Tsuda K, Oshima K, Mori J, Shimmura H. Carfilzomib for relapsed
or refractory multiple myeloma. Lancet Oncol. 2018 Jan;19(1):e1. doi:
10.1016/S1470-2045(17)30859-8. PMID: 29304356.
33. Tsuda K, Tanimoto T, Mori J, Kosugi K, Komatsu T. Targeted-release budesonide
therapy for IgA nephropathy. Lancet. 2017 Dec 16;390(10113):2625. doi:
10.1016/S0140-6736(17)32145-1. PMID: 29256403.
34. Tanimoto T, Oshima K, Tsuda K, Mori J, Shimmura H. Rituximab and autologous
stem-cell transplantation for high-risk diffuse large B-cell lymphoma. Lancet
Oncol. 2017 Oct;18(10):e557. doi: 10.1016/S1470-2045(17)30706-4. PMID:
28971816.

35. Tanimoto T, Mori J, Oshima Y. Characteristics of Novel Therapeutics andPostmarket Safety Events. JAMA. 2017 Sep 19;318(11):1067. doi:
10.1001/jama.2017.11513. PMID: 28975300.
36. Mori J, Yanada M, Uchida N, Fukuda T, Sakura T, Hidaka M, Watakabe-Inamoto K,Kanamori H, Ogawa H, Ichinohe T, Tanaka J, Atsuta Y, Yano S. Outcomes ofAllogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Patients with Abnormalities of the Short Arm of Chromosome 17. Biol Blood
Marrow Transplant. 2017 Aug;23(8):1398-1404. doi: 10.1016/j.bbmt.2017.04.020.
Epub 2017 Apr 25. PMID: 28455005.
37. Tanimoto T, Tsuda K, Mori J. Temporal Changes in Subsequent Malignancies
Among Childhood Cancer Survivors. JAMA. 2017 Jun 20;317(23):2451. doi:
10.1001/jama.2017.6020. PMID: 28632860.
38. Mori J, Oshima K, Tanimoto T. Blinatumomab for Acute Lymphoblastic Leukemia.
N Engl J Med. 2017 Jun 8;376(23):e49. doi: 10.1056/NEJMc1704012. PMID:
28594155.
39. Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines foruniversal health coverage. Lancet. 2017 May 13;389(10082):1880-1881. doi:
10.1016/S0140-6736(17)31211-4. Epub 2017 May 11. PMID: 28513444.
40. Tanimoto T, Tsuda K, Mori J. Zoledronic Acid Dosing Interval for MetastaticCancer. JAMA. 2017 Apr 11;317(14):1477. doi: 10.1001/jama.2017.2558. PMID:28399242.
41. Kato S, Nishimura KI, Mori JI. [Update on recent progress in vitamin D
research. Molecular basis of epigenetic regulation by vitamin D via its
nuclear receptor.]. Clin Calcium. 2017;27(11):1543-1550. Japanese. PMID:29074826.
42. Mori J, Tsuda K, Tanimoto T. Inotuzumab Ozogamicin for Acute Lymphoblastic
Leukemia. N Engl J Med. 2016 Nov 24;375(21):2100. doi: 10.1056/NEJMc1612040.
PMID: 27959721.
43. Sonoda Y, Higuchi A, Morita T, Mori J, Shimmura H. Intensive blood pressurelowering. Lancet. 2016 Jun 4;387(10035):2291. doi: 10.1016/S01406736(16)30688-2. PMID: 27302267.

44. Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N, Kobayashi T, Fukuda T,Kanamori H, Miyamura K, Takahashi S, Eto T, Hirokawa M, Mori S, Nagamura T,Atsuta Y, Takami A. Outcomes of allogeneic hematopoietic cell transplantationin patients with biphenotypic acute leukemia. Ann Hematol. 2016
Jan;95(2):295-300. doi: 10.1007/s00277-015-2536-3. PMID: 26499506.
45. Shimmura H, Tsubokura M, Kato S, Akiyama J, Nomura S, Mori J, Tanimoto T, AbeK, Sakai S, Kawaguchi H, Tokiwa M. Whole body counter assessment of internal
radiocontamination in patients with end-stage renal disease living in areas
affected by the Fukushima Daiichi nuclear power plant disaster: aretrospective observational study. BMJ Open. 2015 Dec 7;5(12):e009745. doi:
10.1136/bmjopen-2015-009745. PMID: 26644125; PMCID: PMC4679891.